철결핍성 빈혈 치료 시장 보고서 : 동향, 예측, 경쟁 분석(-2030년)

Iron Deficiency Anemia Therapy Trends and Forecast

The future of the global iron deficiency anemia therapy market looks promising with opportunities in the hospital, clinic, and home healthcare markets. The global iron deficiency anemia therapy market is expected to reach an estimated $4.6 billion by 2030 with a CAGR of 5.3% from 2024 to 2030. The major drivers for this market are high incidence of iron deficiency anemia is attributed to insufficient iron intake from food and excessive loss of red blood cells, particularly affecting women and children, surge in female population, and growing awareness towards women health.

A more than 150-page report is developed to help in your business decisions.

Iron Deficiency Anemia Therapy by Segment

The study includes a forecast for the global iron deficiency anemia therapy by therapy type, end use, and region.

Iron Deficiency Anemia Therapy Market by Therapy Type [Shipment Analysis by Value from 2018 to 2030]:

• Oral Iron Therapy
• Parenteral Iron Therapy
• Red Blood Cell Transfusion

Iron Deficiency Anemia Therapy Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

• Hospitals
• Clinics
• Home Healthcare

Iron Deficiency Anemia Therapy Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Iron Deficiency Anemia Therapy Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies iron deficiency anemia therapy companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the iron deficiency anemia therapy companies profiled in this report include-

• Abbvie
• Akebia Therapeutics
• AMAG Pharmaceuticals
• Daiichi Sankyo
• Pharmacosmos
• Sanofi
• Johnson and Johnson
• Fresenius
• ViforPharma
• Rockwell Medical

Iron Deficiency Anemia Therapy Market Insights

Lucintel forecasts that parenteral iron therapy will remain the largest segment over the forecast period due to high demand for patients receiving recombinant erythropoietin therapy or suffering from chronic diseases that hinder iron absorption through oral means.

Within this market, hospital will remain the largest segment as it is equipped to handle complex cases and has necessary facilities and staffs to manage patients.

North America will remain the largest region over the forecast period due to surge in healthcare spending, increasing prevalence of iron deficiency anemia among the population, and the presence of key market players in the region.

Features of the Global Iron Deficiency Anemia Therapy Market

Market Size Estimates: Iron deficiency anemia therapy market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Iron deficiency anemia therapy market size by therapy type, end use, and region in terms of value ($B).

Regional Analysis: Iron deficiency anemia therapy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different therapy types, end uses, and regions for the iron deficiency anemia therapy market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the iron deficiency anemia therapy market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the iron deficiency anemia therapy market size?

Answer: The global iron deficiency anemia therapy market is expected to reach an estimated $4.6 billion by 2030.

Q2. What is the growth forecast for iron deficiency anemia therapy market?

Answer: The global iron deficiency anemia therapy market is expected to grow with a CAGR of 5.3% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the iron deficiency anemia therapy market?

Answer: The major drivers for this market are high incidence of iron deficiency anemia is attributed to insufficient iron intake from food and excessive loss of red blood cells, particularly affecting women and children, surge in female population, and growing awareness towards women health.

Q4. What are the major segments for iron deficiency anemia therapy market?

Answer: The future of the global iron deficiency anemia therapy market looks promising with opportunities in the hospital, clinic, and home healthcare markets.

Q5. Who are the key iron deficiency anemia therapy market companies?

Answer: Some of the key iron deficiency anemia therapy companies are as follows:

• Abbvie
• Akebia Therapeutics
• AMAG Pharmaceuticals
• Daiichi Sankyo
• Pharmacosmos
• Sanofi
• Johnson and Johnson
• Fresenius
• ViforPharma
• Rockwell Medical

Q6. Which iron deficiency anemia therapy market segment will be the largest in future?

Answer: Lucintel forecasts that parenteral iron therapy will remain the largest segment over the forecast period due to high demand for patients receiving recombinant erythropoietin therapy or suffering from chronic diseases that hinder iron absorption through oral means.

Q7. In iron deficiency anemia therapy market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to surge in healthcare spending, increasing prevalence of iron deficiency anemia among the population, and the presence of key market players in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the iron deficiency anemia therapy market by therapy type (oral iron therapy, parenteral iron therapy, and red blood cell transfusion), end use (hospitals, clinics, and home healthcare), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Iron Deficiency Anemia Therapy Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Iron Deficiency Anemia Therapy Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Iron Deficiency Anemia Therapy Market by Therapy Type
  • 3.3.1: Oral Iron Therapy
  • 3.3.2: Parenteral Iron Therapy
  • 3.3.3: Red Blood Cell Transfusion
• 3.4: Global Iron Deficiency Anemia Therapy Market by End Use
  • 3.4.1: Hospitals
  • 3.4.2: Clinics
  • 3.4.3: Home Healthcare

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Iron Deficiency Anemia Therapy Market by Region
• 4.2: North American Iron Deficiency Anemia Therapy Market
  • 4.2.2: North American Iron Deficiency Anemia Therapy Market by End Use: Hospitals, Clinics, and Home Healthcare
• 4.3: European Iron Deficiency Anemia Therapy Market
  • 4.3.1: European Iron Deficiency Anemia Therapy Market by Therapy Type: Oral Iron Therapy, Parenteral Iron Therapy, and Red Blood Cell Transfusion
  • 4.3.2: European Iron Deficiency Anemia Therapy Market by End Use: Hospitals, Clinics, and Home Healthcare
• 4.4: APAC Iron Deficiency Anemia Therapy Market
  • 4.4.1: APAC Iron Deficiency Anemia Therapy Market by Therapy Type: Oral Iron Therapy, Parenteral Iron Therapy, and Red Blood Cell Transfusion
  • 4.4.2: APAC Iron Deficiency Anemia Therapy Market by End Use: Hospitals, Clinics, and Home Healthcare
• 4.5: ROW Iron Deficiency Anemia Therapy Market
  • 4.5.1: ROW Iron Deficiency Anemia Therapy Market by Therapy Type: Oral Iron Therapy, Parenteral Iron Therapy, and Red Blood Cell Transfusion
  • 4.5.2: ROW Iron Deficiency Anemia Therapy Market by End Use: Hospitals, Clinics, and Home Healthcare

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Iron Deficiency Anemia Therapy Market by Therapy Type
  • 6.1.2: Growth Opportunities for the Global Iron Deficiency Anemia Therapy Market by End Use
  • 6.1.3: Growth Opportunities for the Global Iron Deficiency Anemia Therapy Market by Region
• 6.2: Emerging Trends in the Global Iron Deficiency Anemia Therapy Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Iron Deficiency Anemia Therapy Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Iron Deficiency Anemia Therapy Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Abbvie
• 7.2: Akebia Therapeutics
• 7.3: AMAG Pharmaceuticals
• 7.4: Daiichi Sankyo
• 7.5: Pharmacosmos
• 7.6: Sanofi
• 7.7: Johnson and Johnson
• 7.8: Fresenius
• 7.9: ViforPharma
• 7.10: Rockwell Medical